20 years with personalized medicine.
The article, New Era of Personalized Medicine: Targeting Drugs for Each Unique Genetic Profile, 16 April 1999, kickstarted what we call the paradigm change of the 'one-size-fits-all' approach, and it's still under change and development. Today, personal medicine is in competition with other terms such as 'precision medicine' or 'stratified medicine', and is no longer the preferred term for describing the individualized health care approach. Our network member Jan Trøst Jørgensen, Director at Dx-Rx Institute, who we in Biopeople see as one of the grand old men of this era, has written an excellent article : Twenty Years with Personalized Medicine: Past, Present and Future of Individualized Pharmacotherapy. We bring some quotes and extracts in collaboration with Jan Trøst Jørgensen for you here.
”The twenty years with personalized medicine have taught us that ‘one size does not fit all’, and for most diseases therapy need to be individualized.”
Today, as for 20 years ago, when the term 'personalized medicine' was presented to the public, the discusssion still take several of the same important arguments for an individual therapy into account, as described back then. The main argument is still, that there is poor efficacy of the current pharmacotherapy and that the 'one-size-fits-all' approach doesn't take the disease heterogeneity into account. Jørgensen emphasizes that we still focus on the development and use of predictive biomarkers.
”Predictive biomarkers are important elements in realization of a more personalized therapy, probably the single most important one. These biomarkers are used to identify patients who are likely to experience a favorable outcome of a medical product and thereby enable individualization and avoid inappropriate treatments.”
In present time the paradigm shift has resulted in development of more effective drugs.
”Within hematology and oncology, the drug-diagnostic codevelopment model has for the past twenty years produced a number of effective drugs. Today, more than 30 different drugs have been approved with a predictive biomarker and their use in the clinic is guided by a companion diagnostic test.”
”Personalized medicine arises out of the idea of improving and individualizing pharmacotherapy. However, this concept has spread to most areas of our healthcare system and today greatly influences the way we implement initiatives related to diagnosis, prevention and treatment. Despite we have achieved at lot, we are far from the end of the road. In the years to come we will need to see the ideas of personalized medicine get foothold outside hematology and oncology.”
In Biopeople we agree with Jan Trøst Jørgensen that we are far from the end of the road.
"Personalized medicine is on the national agenda and as such a focus area for Danish Life Science as well as Biopeople's efforts to catalyze collaboration between the various actors in the field," says Randi Krogsgaard, Cluster Manager, Biopeople.
We keep an eye on the development within the area of personalized medicine, and we are involved in various national and international project which have a focus on biomarkers' importance in the research and development of personalized medicine. As a part of our commitment in the Interreg project, 'Biomarker Commercialization (BIC)', led by Ideklinikken at Aalborg University Hospital, we are involved in developing a biomarker tool for researchers and SME's. For the last two years Biopeople has been lead partner in a national project "Biomarkers as an emerging growth area in Denmark", which resulted in a White Paper with ideas for innovation and capacity building in the Biomarker area. This project was a partnership between Biopeople, Bioneer, Brandbase and InfinIT. Read more at https://biomarkers.dk/
Read the abstract here: (http://theoncologist.alphamedpress.org/content/early/2019/04/02/theoncologist.2019-0054.abstract)